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The Dietary Reference Intakes (DRI)-monograph (USA/Canada) states that the estimated
average requirement (EAR) of vitamin E for men and women of any age is 12 mg/day.
The EAR value is based on in vitro hemolysis in young males; a surrogate endpoint
without any direct validity. The EAR is then extrapolated to females and older males.
The validity of the EAR level is therefore questionable. Total mortality is an outcome of
direct clinical relevance. Investigating the effect of long-term dietary vitamin E intake level
on mortality in a randomized trial is, however, not feasible. Nevertheless, the effect of
dietary vitamin E intake can be investigated indirectly from the effects of a fixed-level
vitamin E supplement administered to participants on variable levels of dietary vitamin E
intake. If vitamin E intake below the EAR is harmful, then vitamin E supplement should
be beneficial to those people who have dietary vitamin E intake level below the EAR. The
purpose of this study was to analyze the association between dietary vitamin E intake and
the effect of 25mg/day of vitamin E supplement on total mortality in Finnish male smokers
aged 50–69 years in the Alpha-Tocopherol-Beta-Carotene (ATBC) Study. The effect
of vitamin E supplement was estimated by Cox regression. Among participants who
had dietary vitamin C intake of 90 mg/day and above, vitamin E supplement increased
mortality by 19% (p= 0.006) in those aged 50–62 years, but decreased mortality by 41%
(p = 0.0003) in those aged 66–69 years. No association between vitamin E supplement
effect and dietary vitamin E intake was found in these two groups, nor in participants
who had dietary vitamin C intake less than 90 mg/day. There is no evidence in any of
the analyzed subgroups that there is a difference in the effect of the 25 mg/day vitamin
E supplement on males on dietary vitamin E intakes below vs. above the EAR of 12
mg/day. This analysis of the ATBC Study found no support for the ‘estimated average
requirement’ level of 12 mg/day of vitamin E for older males.
Trial registration: ClinicalTrials.gov, identifier: NCT00342992.
Keywords: adverse effect, alpha-tocopherol, ascorbic acid, biomarkers, evidence-based medicine, nutrition
policy, nutritional requirements, reference values
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INTRODUCTION
The Dietary Reference Intakes (DRI)-monograph of the USA and
Canada states that the recommended dietary allowance (RDA)
for men and women of any age is 15 mg/day. The RDA value is
based on the estimated average requirement (EAR) of 12 mg/day
of vitamin E [(1), p. 231–9]. This EAR value is, in turn, based on
the following reasoning.
First, in 1963 Horwitt et al. had studied 4 young males
and found that at plasma α-tocopherol concentrations lower
than 12 µmol/L, an increase in hydrogen peroxide-induced
hemolysis above 12 percent was observed in vitro (2). In the
DRI, a plasma α-tocopherol concentration of 12 µmol/L was
therefore associated with “normal” hydrogen peroxide-induced
hemolysis [(1), p. 233]. Second, with young males in laboratory
conditions, Horwitt had found that the plasma α-tocopherol level
of 12 µmol/L was associated with the intake of 12 mg/day α-
tocopherol (3), and that intake level was selected as the EAR [(1),
p. 234]. Third, the authors of the DRI-monograph assumed that
there were no physiological differences in vitamin E requirement
between young and old adults, and concluded that “adults ages 51
years and older appear to have the same vitamin E requirement as
younger adults” [(1), p. 238].
The above approaches are flawed. First, hydrogen peroxide-
induced hemolysis in a test tube is a surrogate endpoint and
the DRI-monograph does not provide any evidence that this
surrogate correlates with any clinically relevant outcome [(1), p.
186–283]. The use of surrogates has been popular in medicine
since measuring surrogates is much quicker and much less
expensive thanmeasuring clinically relevant outcomes. However,
the wide-spread use of surrogates has been severely criticized.
There are numerous examples that demonstrate that the effects
on surrogate endpoints can diverge from the effects on clinically
relevant outcomes (4–9). Second, several surveys in the free-
living population have shown that the correlation between
dietary vitamin E intake level and plasma vitamin E level is
very low [(1), p. 210]. Therefore, it seems inappropriate to use
a small study with males in laboratory conditions to infer a
dose for males in the general population. Finally, there is much
evidence that oxidative stress increases with age (10–17), and
therefore, as an antioxidant, vitamin E might have different
effects depending on the age of the individual. However, the
authors of the DRI did not express any caution about this in
the extrapolation of an EAR value derived from young males
to older males and women. All three steps to establish the EAR
for older people are highly speculative, and the EAR level for
males aged 51 years and older is therefore extremely arbitrary.
Moreover, the problems of surrogates (4–6) and the increased
oxidative stress phenomenon in older people (10–12) were well
known long before the DRI recommendations were published
(1), and they should have been considered when deriving the EAR
value. Finally, the DRI recommendations themselves admitted
that there is no meaningful correlation between dietary vitamin
E intake and plasma vitamin E level.
In contrast to the hydrogen-peroxide induced hemolysis in
a test tube, mortality is an outcome of direct clinical relevance.
Higher dietary vitamin E intake levels have been associated
with lower mortality [(1), p. 212–3], but non-nutritional and
nutritional confounders can bias correlations in cohort studies.
Investigating the direct effect of long-term dietary vitamin E
intake level on mortality in a controlled trial is not feasible.
Nevertheless, the effect of dietary vitamin E intake on mortality
can be investigated indirectly from the effects of a fixed-level
vitamin E supplement given to subjects with variable levels of
dietary vitamin E intake. If dietary vitamin E intakes below the
stated EAR are harmful, then vitamin E supplement should be
beneficial to people with vitamin E intakes below the EAR.
The purpose of this study was to analyze the association
between dietary vitamin E intake and the effect of vitamin
E supplementation on mortality in the Alpha-Tocopherol-
Beta-Carotene (ATBC) Study. The ATBC Study was a large
randomized trial, which examined the effects of 50 mg/day of all
rac-α-tocopheryl acetate and 20 mg/day β-carotene on the risk of
lung cancer in male smokers aged 50–69 years (18, 19). The all
rac-α-tocopheryl acetate has only 50% of the vitamin E activity
as redefined in the DRI in 2000 [(1), p. 191], which indicates that
the actual biologically active supplement dose was 25 mg/day of
the redefined vitamin E.
A previous analysis of the ATBC Study data showed that the
effect of vitamin E supplement on mortality was significantly
modified by the combination of age and dietary vitamin C
intake (20). The effect of vitamin C was not explained by other
substances in fruit and vegetables (20). Old age is associated with
increased oxidative stress (10–17) and there is strong evidence
of an interaction between vitamins C and E both in vitro and in
vivo (21–30), whichmakes these two variables plausible modifiers
of the vitamin E supplement effects (20). If the EAR level of 12
mg/day is a biologically valid estimate, then the effects of vitamin
E supplementation should be different for ATBC participants
with vitamin E intakes below and above the EAR level in the
previously identified groups defined by age and dietary vitamin
C intake.
METHODS
Participants
The design and methods of the ATBC Study examining the
effects of vitamin E [all rac-α-tocopheryl acetate, AT, 50 mg/day,
which corresponds to 25 mg/day of redefined vitamin E [(1), p.
191] and β-carotene (BC, 20 mg/day) on the incidence of lung
cancer and other cancers have been described earlier (18, 19).
The ATBC Study is registered at ClinicalTrials.gov under the
identifier NCT00342992.
In brief, male participants aged 50–69 years had to smoke
≥5 cigarettes per day at entry to be eligible, and those
enrolled in the trial (N = 29,133) were randomized to one
of four intervention arms and administered placebo, AT, BC
or AT + BC, using a 2 × 2 factorial design. Compliance
with supplementation was high: 90% of the participants took
more than 90% of their prescribed capsules during their active
participation in the trial; there were no differences in capsule
consumption among the intervention groups. Compared with
the baseline levels, supplementation increased the serum level
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of α-tocopherol by 50%. The intervention continued until 30
April 1993. The trial was approved by the institutional review
boards and all participants gave written informed consent. This
study was restricted to 27,111 participants for whom dietary data
were available.
Baseline Characteristics
Before randomization at baseline, the men completed
questionnaires on their general background characteristics.
At the first baseline visit, participants were given a separate,
detailed dietary history questionnaire for completion at home
and the questionnaire was returned and reviewed (31). The
questionnaire included a 63-page picture booklet with 122
photographs, and asked about portion sizes for 276 common
foods and mixed dishes and the usual frequency of their
consumption over the previous 12 months. The validity of the
dietary history questionnaire was assessed by comparing it with
the food consumption records of 190 participants for 12 separate
2-day periods distributed evenly over 6 months. Between 75%
and 80% of participants categorized by food consumption
records obtained from the dietary history questionnaire were in
the same vitamin E intake quintile or in the within-one-quintile
category, and 74–76% were in the same vitamin C intake quintile
or in the within-one-quintile category (31). In the reproducibility
study, participants filled in the food use questionnaire three
times, at three-month intervals. The intraclass correlation was
0.70 for dietary vitamin E intake and 0.69 for dietary vitamin C
intake as determined by the reproducibility analysis (31).
Dietary data were not available for 2,022 of the 29,133
participants. In the ATBC Study, dietary vitamin E intake was
estimated as α-tocopherol equivalents. The DRI monograph
instructs using a multiplier 0.80 for the transformation of α-
tocopherol equivalents to the redefined vitamin E dose [(1), p.
244–5], however, the multiplier of 0.85 was used in this study as
it was based on Finnish data (32). Using themultiplier 0.80 has no
effect on the trend tests, and has only minor effects in the groups
by dietary vitamin E intake (not shown).
The Vitamin E Variables
In this analysis, the term “vitamin E intake” refers to the dietary
vitamin E intake at the baseline of the ATBC Study (31). The term
“vitamin E supplementation” refers to the administration of 25
mg/day of the redefined vitamin E as all rac-α-tocopheryl acetate
(50 mg/day) [(1), p. 191]. Thus, the total daily intake of vitamin
E among the vitamin E participants was the sum of the dietary
vitamin E intake plus the supplement dose of 25 mg/day.
Outcome and Follow-up Time
Deaths were identified in the National Death Registry as
previously described (18, 19). Follow-up time for each participant
began from the day of randomization, and continued until death
or the end of the trial (30 April, 1993). The median follow-up
time of the participants in the present analysis was 6.1 years, and
there was a total of 158,373 person-years of observation.
Statistical Models
The effect of vitamin E supplementation on mortality was
estimated through Cox regression models. The risk ratio
(RR) and the 95% confidence interval (CI) of the RR were
calculated using PROC PHREG in SAS (release 9.4, SAS
Institute, Inc., Cary, NC, USA). Participants administered
vitamin E (AT and AT+BC) were compared with those
not administered vitamin E (the no-vitamin E participants;
placebo and BC).
The potential modification of vitamin E supplement effect
by dietary vitamin E intake, and by β-carotene supplementation
was examined as follows. To test the statistical significance
of interaction between vitamin E supplement and a potential
modifying factor, the supplement and modifying factor were
first added to the Cox regression model. Then the interaction
term was added to the model. The statistical significance of
the interaction was thereafter calculated by using the likelihood
ratio test, see Supplementary Material. As to supplementation,
the analyses were carried out following the intention-to-treat
principle. Deaths were identified in the National Death Registry
which registers all deaths that occur in Finland, thus the loss-to-
follow-up is insignificant (18, 19).
RESULTS
The Alpha-Tocopherol-Beta-Carotene (ATBC) Study recruited
29,133 male smokers aged 50–69 years. The characteristics of the
participants have been described previously (18, 19, 33). Among
all participants, vitamin E had no average effect on mortality
(19). Dietary data for vitamins C and E were available for 27,111
participants to whom this analysis is restricted. An earlier analysis
showed that dietary vitamin C intake and age modified the effect
of vitamin E supplementation (20), and the following analysis
is an extension of those previous findings. Since vitamin E
supplement effect was different for males who had high and low
dietary vitamin C intake, the participants are divided here into
two subgroups by the vitamin C intake of 90 mg/day, which is
close to the median.
Vitamin E supplement had no effect on mortality in
participants who had vitamin C intake <90 mg/day. There was
no variation in vitamin E supplement effect by dietary vitamin E
effect (Table 1). There is no evidence that vitamin E supplement
was beneficial for the 11,223 participants who had dietary vitamin
E intake less than the stated EAR of 12 mg/day (1), with RR =
1.00 (95% CI 0.91-1.11; based on 735/736 deaths in the vitamin
E and no-vitamin E groups). Stratification by age is not shown in
Table 1 since the lack of vitamin E supplement effect is uniform
over the three age groups.
In those who had baseline vitamin C intake 90 mg/day and
above, the effect of vitamin E supplement was modified by age
(Table 2). Within the three age groups there was no evidence
that vitamin E supplement effect was modified by dietary
vitamin E intake. The confidence intervals extensively overlap
and the tests of interaction between vitamin E supplement
and continuous dietary vitamin E intake found no significant
associations (Table 2).
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TABLE 1 | ATBC Study participants with dietary vitamin C intake <90 mg/day by
dietary vitamin E intake.
Dietary vitamin E intake Test of
trenda
P
Range (mg/day) 1.4–8 9–11 12–58
Median intake (mg/day) 6.5 10.1 15.3
Vitamin E supplement effectb
RR
(95% CI)
1.03
(0.92–1.16)
0.92
(0.73–1.15)
1.01
(0.81–1.26)
0.5
Deaths (vitE/no-vitE) 588/579 147/157 160/156
N 8740 2483 2344
aTest of interaction between vitamin E supplement effect and dietary vitamin E intake as
a continuous variable. The linear trend was tested and the p > 0.05 value indicates that
there is no evidence that the vitamin E supplement effect varies by dietary vitamin E intake
level.
bThe Cox regressionmodel comparing participants who received vitamin Ewith those who
did not. For the 11,223 participants who had dietary vitamin E intake below 12 mg/day
(median 7.1 mg/day), which is the EAR level for ages 51 years and older [(1), p 238], the
RR = 1.00 (95% CI 0.91–1.11).
RR, risk ratio; CI, confidence interval.
Vitamin E supplement was significantly harmful for the
younger ATBC participants aged 50–62 years who had vitamin
C intakes of 90 mg/day and above (Table 2 and Figure 1A).
On average, the 25 mg/day vitamin E supplement increased
mortality by RR = 1.19 (95% CI 1.05–1.35; p = 0.006). There
is no evidence that vitamin E supplement was beneficial for the
7,149 participants who had dietary vitamin E intake less than the
EAR of 12 mg/day (1), with RR = 1.18 (95% CI 1.01–1.38; p =
0.034; based on 356/301 deaths in the vitamin E and no-vitamin
E groups). The median vitamin E intake was 9.0 mg/day in the
7,149 participants who had intake below the EAR.
In the older ATBC participants aged 66–69 years who had
vitamin C intake 90 mg/day and above, vitamin E supplement
was significantly beneficial (Table 2 and Figure 1B). On average,
vitamin E supplement decreased mortality by RR = 0.59 (95%
CI 0.44–0.79; p = 0.0003). A statistically significant benefit of
vitamin E supplementation was seen in those who had dietary
vitamin E intake of <9 mg/day and also in those who had
dietary vitamin E intake 12 mg/day and above. The confidence
interval for the middle group (10 mg/day) extensively overlaps
with the groups on the sides. The significant benefit of vitamin
E supplementation in the right-hand-side group indicates that
the median intake of 15 mg/day was sub-optimal, although 15
mg/day is the RDA level and has been argued to cover the
requirement of 97.5% of people [(1), p. 23,238].
Since half of the ATBC Study participants were given β-
carotene and half were not, the possible interaction between
β-carotene and vitamin E administration was examined in the
three age groups who had vitamin C intake of 90 mg/day and
over (Table 3). There was no evidence found that the vitamin E
supplement effect was modified by the β-carotene supplement. In
the younger participants aged 50–62 years, the point estimates for
harm of vitamin E supplement were very similar in both groups.
In the older participants aged 66–69 years group, the estimates
TABLE 2 | ATBC Study participants with dietary vitamin C intake ≥90 mg/day by
dietary vitamin E intake.
Dietary vitamin E intake Test of
trenda
p
Range (mg/day) 3.1–8 9–11 12–53
Median intake (mg/day) 7.5 10.3 15.2
Age 50–62 years
Vitamin E supplement effectb
RR
(95% CI)
1.15
(0.93–1.41)
1.23
(0.98–1.54)
1.20
(0.97–1.47)
0.3
Deaths (vitE/no-vitE) 188/167 168/134 196/168
N 3591 3558 4299
Age 63–65 years
Vitamin E supplement effectb
RR
(95% CI)
1.17
(0.77–1.75)
0.78
(0.46–1.31)
0.69
(0.42–1.13)
0.09
Deaths (vitE/no-vitE) 52/42 27/29 27/39
N 498 350 376
Age 66–69 years
Vitamin E supplement effectb
RR
(95% CI)
0.59
(0.37–0.92)
0.78
(0.46–1.31)
0.40
(0.22–0.74)
0.7
Deaths (vitE/no-vitE) 30/52 27/31 14/41
N 360 263 249
aTest of interaction between vitamin E supplement effect and dietary vitamin E intake as a
continuous variable. The linear trend was tested and p > 0.05 value indicates that there
is no evidence that the vitamin E supplement effect varies by dietary vitamin E intake level.
bThe Cox regression model compares participants who received vitamin E
supplementation with those who did not.
RR, risk ratio; CI, confidence interval.
for benefit were also very similar. Thus, the estimates of effect in
Table 2 are not biased by β-carotene administration.
Among the participants who had vitamin C intake 90
mg/day and above, the relationship between age and vitamin E
supplement effect is shown in Figure 2. Allowing each of the
three age groups of Table 2 their own vitamin E supplement
effect improves the Cox regression model significantly. However,
age was also analyzed as a continuous variable since interaction
between vitamin E supplement effect with continuous age refutes
the possibility that explorative selection of the cut-points might
have caused a spurious interaction with age. The dotted diagonal
slope in Figure 2 tests whether the effect of vitamin E supplement
is constant over age, and a uniform effect over age as a
continuous variable is rejected. The regression line should not
be extrapolated beyond the median vitamin E intakes of the
youngest and oldest participants, but the slope indicates that
there are substantial changes in vitamin E effects in the age region
of∼60–65 years.
DISCUSSION
Main Findings
No evidence was found to indicate that the effect of vitamin
E supplementation might differ for those who had dietary
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FIGURE 1 | The effect of vitamin E supplement by dietary vitamin E intake. (A)
Participants aged 50–62 years at baseline. (B) Participants aged 66–69 years
at baseline. The three vitamin E intake groups of Table 2 are plotted at the
median vitamin E intake of the respective group. The points indicate the
estimates and the vertical lines indicate their 95% CIs. The solid horizontal
lines indicate the average effect of vitamin E supplement in the younger (A)
and older (B) participants, and the vertical bars on the right-hand side indicate
the 95% CI for the average effect. The dashed horizontal lines indicate the no
effect level. The arrows indicate the levels of the EAR and the RDA for vitamin
E (1).
vitamin E intake below vs. above the EAR level for vitamin
E. This lack of difference in the vitamin E supplementation
effect below and above the EAR level was seen separately in
four subgroups of the ATBC cohort. In two of the subgroups,
vitamin E supplementation had a significant effect on mortality,
but the effect was closely similar on both sides of the EAR
limit. In the older participants who had vitamin C intakes
over 90 mg/day and dietary vitamin E intake over 12 mg/day,
the vitamin E supplement was significantly beneficial even
though the median dietary vitamin E intake in that subgroup
was 15 mg/day, which is the RDA (2000) level for vitamin E
(1). Therefore, the dietary vitamin E intake of that subgroup
should cover the requirement of 97.5% of people [(1), p.
23,238]. The significant variation in vitamin E supplement
effect by age and dietary vitamin C intake in the males of
the ATBC cohort is inconsistent with a uniform EAR level for
all adults.
TABLE 3 | ATBC Study participants with dietary vitamin C intake ≥90 mg/day by
β-carotene administration.
No-β-carotene
participants
β-Carotene
participants
Test of
interactiona
p
Age 50–62 years
Vitamin E supplement effectb
RR (95% CI) 1.20
(1.00–1.44)
1.17
(0.99–1.39)
0.9
Deaths (vitE/no-vitE) 259/222 293/247
N 5710 5738
Age 63–65 years
Vitamin E supplement effectb
RR
(95% CI)
0.76
(0.52–1.11)
1.04
(0.71–1.53)
0.3
Deaths (vitE/no-vitE) 50/60 56/50
N 609 615
Age 66–69 years
Vitamin E supplement effectb
RR
(95% CI)
0.57
(0.38–0.86)
0.60
(0.39–0.91)
0.9
Deaths (vitE/no-vitE) 37/59 34/65
N 429 443
aTest of interaction between vitamin E supplementation and β-carotene supplementation.
The p> 0.05 value indicates that there is no evidence that the vitamin E supplement effect
is influenced by β-carotene supplementation in these groups.
bThe Cox regression model compared participants who had received vitamin E with those
who did not separately in the no-β-carotene participants and the β-carotene participants.
RR, risk ratio; CI, confidence interval.
FIGURE 2 | Relationship between baseline age and the effect of vitamin E
supplement in males who had dietary vitamin C intake ≥90 mg/day. The three
age groups of Table 2 are plotted at the median age of each group. The
points indicate the estimates and the vertical lines indicate their 95% CI. The
uniformity of the vitamin E supplement effect over age was tested by adding a
dummy variable for vitamin E effect for the 63–65 year and the ≥66 year age
groups, allowing each of the three age groups of Table 2 their own vitamin E
effect. The regression model was improved by χ2(2df) = 21.5, p = 0.00002,
compared with the model with a uniform vitamin E supplement effect over all
ages. The dotted diagonal line shows the Cox regression model with age as a
continuous variable. Allowing the slope, the regression model was improved
by χ2(1df) = 12.8, p = 0.0004, compared with the model with a uniform vitamin
E supplement effect over all ages.
Frontiers in Nutrition | www.frontiersin.org 5 March 2020 | Volume 7 | Article 36
Hemilä Requirement for Vitamin E
Three Alternative Paradigms on Vitamins
and Health
For the interpretation of the current findings, it is useful to
consider three different paradigms that have been proposed for
the relationship between vitamin intake levels and health.
Many vitamins were found as the explanation for a severe
disease, such as the deficiency of vitamin C was identified as
the explanation for scurvy. This background led to the ‘nutrient
need’ -paradigm (34–37). Preventing scurvy was the premise of
the US RDA nutritional recommendations for vitamin C from
the 1940s until the 10th edition in 1989 (38, 39). Approximately
10 mg/day of vitamin C prevents overt symptoms of scurvy, and
this level was termed the “need” or “requirement.” Nevertheless,
the concept of ‘nutrient need’ gives the false impression that an
exact dose of a vitamin is required daily, so that larger amounts
could not have any active physiological effects, but would simply
provide passive reserves. However, the physiological purpose of
vitamin C is not to remain “in reserve against scurvy” but to
participate in chemical reactions in the body, and the rates of
these reactions depend on concentrations, which further depend
on the levels of intake (34–37, 40–44). Thus, an exact level of
“nutrient need” or “requirement” that sharply distinguishes a
frank deficiency from “normal health” is not a sound concept
from the biochemical point of view. The RDA for vitamin C
(1989) was set at 60 mg/day to “provide an adequate margin of
safety” against scurvy, arguing that “this level of intake will prevent
signs of scurvy for at least 4 weeks” in the fictional condition that
a person completely stops taking any vitamin C [(38), p. 118].
The “optimal intake” -paradigm also has its origins in the
early part of the previous century. Charles Glen King (1936)
commented that “The fact that there is a wide zone of vitamin
deficiency between scurvy and optimum health is of more interest
in relation to human health than the problem of clinical scurvy”
[(45), p. 254]. From his own research on guinea pigs he also
concluded that “it is evident from the data presented that the
level of vitamin C intake for optimum in vivo detoxification of
diphtheria toxin is considerably greater than that necessary to
protect from scurvy or to show a favorable growth rate” [(46), p.
8]. The optimal intake approach was further elaborated by Linus
Pauling in the late 1960s (47), and later by other authors (34–
36, 41–44, 48–50). The optimal intake -paradigm is consistent
with gradual changes in the rates of biochemical reactions with
changes in concentrations. Evidently, the optimal intake is not a
sharp peak, but a wide plateau. However, in some contexts the
plateau might start from dose levels that are much higher than
those needed to prevent overt deficiencies. In the RDA (1989), the
lack of concern about optimal intakes was explicitly recognized:
“RDAs are not necessarily optimal levels of intake” [(38), p. 8]. It
seems highly likely that the long-term optimal levels are different
from the doses that make survival possible in the short term,
i.e., doses that prevent frank deficiency diseases (14, 16, 49, 50).
The term “optimal requirement” has been used (42, 43), but
that is a misnomer, since the term “requirement” has a long and
strong history of indicating the minimal dose that prevents overt
deficiency. In contrast, “optimal intake” or “optimal dosage” seem
more accurate terms that do not have similar historical load.
The third view on the vitamin intake levels and health is
the “individuality in nutrition” -paradigm proposed by Roger J
Williams (51–53). The first two paradigms detailed above are
not inconsistent with individuality. The view of the DRI is that
“requirement” has a normal distribution in the population, with
the EAR as its mean with the standard deviation of 10% of
the EAR [(1), p. 23–4,237–9]. However, Williams considered
that people might differ much more greatly so that their
individual differences in requirement are not simply a marginal
variation around themean of a normal distribution. Individuality
in nutrition can have genetic origins (54). One mechanistic
explanation for substantial differences between people in their
individual optimal levels of vitamin intake can be due to
dissimilarities in the binding constants of enzymes (47, 48). In
addition, life style factors and characteristics such as age may
influence the optimal intake levels.
According to Thomas Kuhn, a paradigm defines what kinds
of questions may be asked and what kinds of answers are
plausible (55). One illustration of the influence of a paradigm
in guiding argumentation in nutrition is the topic of vitamin
C and the common cold. In 1971, Pauling published a meta-
analysis in which he showed that there was highly significant
evidence from four placebo-controlled trials that vitamin C is
beneficial against the common cold with p = 0.00002 (56), a
conclusion that has since been corroborated in a large series of
further randomized trials (57, 58). However, the RDA (1989)
recommendations (38) did not base the conclusions on vitamin C
and the common cold on the Pauling meta-analysis, but instead
on the meta-analysis by Thomas Chalmers which concluded that
there was no evidence that vitamin C had effects on colds (59).
Nevertheless, the Chalmersmeta-analysis is flawed as it has errors
in data extraction, in the calculations, and it is inconsistent in its
inclusion criteria for trials (37, 60, 61). In contrast, errors have not
been pointed out in Pauling’s analysis (56). Had the authors of the
RDAmonograph taken any look at the original publications they
would have seen at least some of the problems in the Chalmers
meta-analysis. So, why did they ignore the Paulingmeta-analysis?
This may be explained by confirmation bias which indicates the
tendency to search for and interpret information in a way that
confirms one’s prior beliefs (62). This serves as an example how
the “nutrient need” paradigm, e.g., the belief that vitamin C has
effects only on scurvy, can blind authorities from objectively
looking at evidence that had shown already by 1971 that vitamin
C can influence conditions other than scurvy. Kunkel has also
discussed how belief systems have affected the development of
RDAs and nutrition guidelines in the past and he expected them
to do so also in the future (63).
Are Current Vitamin E Recommendations
Appropriate?
The above three paradigms provide a useful conceptual
background for considering the current findings and the vitamin
E recommendations. Overt vitamin E deficiency symptoms have
never been described in normal individuals consuming diets
low in vitamin E because the vitamin is found in such a great
variety of foods and it is subsequently stored in the body for
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extensive periods. Therefore, the “nutrition need” paradigm is
not applicable to vitamin E because there is no vitamin E
deficiency in the same sense as scurvy is the deficiency of vitamin
C. In the RDA (1989), the approach for vitamin E was pragmatic.
Since there was no evidence of vitamin E deficiency in the
general population, the quantities that people usually obtain from
their diet cannot be too low. This reasoning was the basis for
the RDA (1989): “the allowance, therefore, is based primarily
on customary intakes from U.S. food sources. . . an arbitrary but
practical allowance for male adults of 10mg of [α-tocopherol
equivalents] per day” [(38), p. 103].
In contrast, the EAR for vitamin E in the DRI (2000)
recommendations is based on hydrogen peroxide-induced
hemolysis in vitro, which is a surrogate endpoint without proven
validity to any clinically relevant outcome [(1), p. 232–9].
Furthermore, the authors of the DRI recommendations believed
that the distribution of the “requirement” follows the normal
distribution and that the standard deviation (SD) is 10% of the
EAR [(1), p. 23–4,237–9]. In a normal distribution, the mean
plus 2 SD covers 97.5% of the distribution, and such a level
was labeled as the revised RDA (2000) level: “The Recommended
Dietary Allowance (RDA) is the average daily dietary intake level
that is sufficient to meet the nutrient requirement of nearly all
(97 to 98 percent) apparently healthy individuals” [(1), p. 23].
For vitamin E, this led the authors of the DRI monograph to
calculate that vitamin E intakes at 15 mg/day (i.e., 12 mg/day
+ 20%) would cover the “requirements” of essentially all of
the general population. However, there was no scientific basis
for the assumption that the distribution of ‘requirement’ for
vitamin E might have a SD of 10% (1). Beaton heavily criticized
the assumption of the 10% SD in the calculation of the RDA
(2000): “the ‘scientific basis’ and hence validity of RDAs calculated
with uncertain or assumed variation and unknown distribution
characteristics must be questioned” (64, 65).
Table 1 of the current study challenges the validity of the 12
mg/day as a biologically relevant limit. There was no benefit from
the 25 mg/day vitamin E supplement to the 11,223 low-vitamin
C-participants who had dietary vitamin E intakes less than the
EAR of 12 mg/day. Table 2 of the current study also contradicts
with the 12 mg/day as a valid limit. There is no evidence in any of
the three age groups that there is a difference in the effect of the
25 mg/day vitamin E supplement on males on dietary vitamin
E intakes below vs. above the EAR of 12 mg/day. Thus, these
current findings challenge the status of the 12 mg/day as being
a biologically valid “average requirement” level for males aged 51
years and older.
Although the DRI claims that 15 mg/day would cover the
“requirements” of 97.5% of 51 year-olds and older [(1), p. 238],
the administration of an additional 25 mg/day of vitamin E to the
249 older high-vitamin C participants who already had a median
dietary vitamin E intake of 15 mg/day (i.e., the new RDA), had
a significantly decreased mortality (Table 2). The comparison
within this group was between the dietary vitamin E intake level
of 15mg/day in the no-vitamin E participants and the total intake
of 40 mg/day (= 15 + 25 mg/day) in the vitamin E participants.
Thus, the 12 mg/day as the “estimated average requirement”
of vitamin E for males aged 51 years and older is based on
flawed approach and it is contradicted by empirical data from
the ATBC Study, which found no evidence that such a level has
biological relevance.
The current findings resonate particularly well with the
“individuality in nutrition” -paradigm. The distribution of
vitamin E effects in Tables 1, 2 are inconsistent with one
single level of “average requirement” that applies to the general
population so that there is a normal distribution -type variation
around a uniform mean [(1), p. 23–4]. In contrast, male smokers
of different ages with different vitamin C intakes seem to have
quite a different relationship between the vitamin E dosage
and health effects. In the ATBC Study, very strong evidence
of heterogeneity was also shown for the effects of vitamin E
supplement on the incidence of pneumonia (33, 66–69) and the
common cold (70). These findings further contradict a universal
“average requirement” level for vitamin E.
Although Table 2 gives information about vitamin E dose
dependency in the three age groups, the confidence intervals are
wide and the data points are too sparse for drawing detailed
conclusions about the optimal intake range. Evidently, the
optimal range for the younger males of 50–62 years with high
vitamin C intake is less than 34 mg/day since the administration
of 25 mg/day of vitamin E above the median daily intake of 9
mg/day led to harm (Table 2). The optimal intake in the older
males of 66–69 years with high vitamin C intake appears to
be over 15 mg/day, but there is no basis to conclude whether
the optimum for these individuals might be below or above 40
mg/day (= 15+ 25 mg/day) (Table 2).
Figure 2 indicates that there are changes in the effects of
vitamin E in the age region of 60–65 years. Great changes in
the effects of vitamin E and β-carotene supplementation on the
incidence of the common cold were also observed in the age
range of 60–65 years (70, 71). In addition, the effects of vitamin E
and β-carotene on pneumonia incidence (69, 72) and the effect of
vitamin E on mortality (73) were most evident in the oldest age
range at follow-up.
Adverse Effects of Increased Intakes of
Vitamin E
The DRI recommendations concluded that the tolerable upper
intake level (UL) for vitamin E is 1.0 g/day [(1), p. 255–8]. This
estimate was based on studies on rats, but it is possible that
harms in rats have very different dose-responses than harms in
humans. For example, various life style variables such as smoking,
alcohol intake, and physical activity, and also characteristics of
humans such as age and blood pressure, and the duration of
supplementation of the fat-soluble vitamin might modify the
potential harms of increased intakes of vitamin E. The effects of
such variables cannot be reasonably tested in rats.
The increased mortality in the younger 50–62 year-old
participants (Table 2) of the present study started only after a
lag period of about 3 years, possibly because fat-soluble vitamin
E accumulates slowly (20). In addition to the harm shown for
the younger participants in Table 2, the 0.05 g/day α-tocopherol
supplement in the ATBC study increased the risk of fatal
subarachnoid hemorrhage by 181% (p = 0.005) (74). That harm
wasmost evident in participants with hypertension in whom fatal
subarachnoid hemorrhages increased by 438% (p = 0.03) (75).
Vitamin E supplementationwas also associated with a 14% higher
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risk of pneumonia in ATBC participants who initiated smoking at
an early age (33), but that harm was further modified by current
smoking, lack of leisure-time exercise, body weight and dietary
vitamin C intake, all of which defined groups in which significant
harm occurred (66–68). Finally, vitamin E increased the risk of
tuberculosis by 120% in ATBC participants who smoked heavily
and had a high dietary intake of vitamin C (76, 77). These findings
illustrate that studies on rats can be highly misleading on the
potential adverse effects of long-term vitamin E administration
in particular population groups.
Individual-level analysis is most informative in the
investigation of particular conditions and harms associated
with increased vitamin E intakes. However, significant study-
level harm has also been reported in other randomized trials.
A study on 652 Dutch elderly people found that 0.2 g/day of
vitamin E increased the occurrence of fever with respiratory
infections (p = 0.01) and the total illness duration (p = 0.02)
(78). The HOPE trial found that 0.3 g/day of vitamin E increased
the risk of hospitalization for heart failure by 40% (p = 0.002) in
7,030 participants with the longest treatment and follow-up (79).
The Physicians’ Health Study II found that 0.4 g/day of vitamin
E increased hemorrhagic stroke by 17% (p = 0.04) in 14,641
male physicians (80). The SELECT trial found that 0.4 g/day of
vitamin E increased the incidence of prostate cancer by 17% (p
= 0.01) in 17,433 males (81). All these doses are much lower
than the rat-based UL of 1.0 g/day for humans [(1), p. 255–8].
Furthermore, it is noteworthy that the increase in prostate cancer
incidence started after about a 3-year lag period (81), which is
consistent with the few years lag that was observed before the
increase in mortality in the young ATBC Study subgroup (20).
Critique of the DRI Approach by Max
Horwitt
The two trials on which the EAR level for vitamin E were based,
were carried out by Max Horwitt (2, 3). Interestingly, Horwitt
seriously criticized the approach in the calculation of the EAR
(82). As early as 1963 Horwitt had stated that he had requested
that no specific requirement for vitamin E be adopted on the
basis of his studies. He emphasized that the experimental diets in
the studies had contained large amounts of oxidized unsaturated
fats not found in habitual diets (82). He also pointed out that
millions of people have lived long lives while consuming much
less that 10 mg/day of vitamin E. Thus, according to his opinion,
increasing the assumed ‘requirement’ to 15 mg/day “benefits only
the commercial interests involved in the sale of vitamin E.” Horwitt
was also concerned with setting the tolerable upper intake level
to 1 g/day. He noted that millions of persons swallowed aspirin
each day, and there was already at that time evidence that vitamin
E could enhance the anticoagulant effects of aspirin (83). After
Horwitt’s critique there has emerged much stronger evidence
that vitamin E doses substantially lower than 1 g/day can cause
significant harm in some population groups (20, 66–68, 74–81).
Limitations of the Study
The ATBC participants were all male smokers and they were
born before WWII. Thus, their childhood and youth were very
different compared to those of later generations. In that respect,
it is not evident how far various findings of the ATBC cohort
can be extrapolated to the general current Western population.
However, having such a background does not compromise the
use of the ATBC cohort for the examination of the validity of the
EAR level. The EAR level for vitamin E is the same for smokers
and nonsmokers (1), and therefore, smokers are an appropriate
subpopulation for this type of investigation. In addition, there is
no upper limit for the age of people for whom the EAR is intended
and no restrictions in the cultural and childhood backgrounds
(1). Therefore, the ATBC cohort contributes appropriate data
for the investigation of the biological relevance of the EAR and
the RDA (2000).
The dietary intake of vitamins E and C were estimated at
the baseline of the ATBC Study. Evidently, there are changes in
the food consumption that occur over the years, whereby some
participants increase and some decrease their dietary vitamin
E intake. However, it seems unlikely that such changes might
be large enough to compromise the validity of this analysis
and in any case these changes will reflect what happens in the
population as a whole. In the reproducibility study of the food
use questionnaire, the findings for vitamin C and E were closely
similar (31). Baseline dietary vitamin C intake predicted the effect
vitamin E supplementation on mortality over the intervention
period, and the effect of vitamin C was not explained by other
substances that are present in fruit, vegetables, and berries (20).
If there were dramatic changes in vitamin C intake levels, such
constancy over years could not occur. There seems no basis to
assume that the changes in dietary vitamin E intake could be
substantially greater than the changes in vitamin C intake, so
that they wouldmake the baseline assessment noninformative for
vitamin E.
Finally, the EAR for vitamin E (1) is based on two small
laboratory-based studies by Horwitt in the 1950s, in which
hydrogen peroxide-induced hemolysis was used as the outcome
(2, 3). Thus, the potential limitations of the current study should
not be considered in isolation, but should be considered in
parallel with the limitations of the Horwitt studies.
The Effects of Vitamin E on Elderly Deserve
Further Research
There is much evidence that oxidative stress increases with age
(10–16), and it has been proposed that higher doses of vitamin
E might be beneficial for the elderly (17). The reduction in
mortality by vitamin E supplementation in the oldest ATBC
participants (Table 2, Figure 2) manifested as a longer lifespan.
Among 2,284 men with dietary vitamin C intakes above 90
mg/day who smoked less than one pack of cigarettes per day,
vitamin E extended lifespan by 2 years at the upper limit of the
follow-up age span (73). In addition, vitamin E administration
reduced the incidence of pneumonia by 69% in 2,216males in the
ATBC Study who smoked the least and exercised in their leisure
time. In those 2,216 male smokers, the cumulative occurrence of
pneumonia by the age of 74 years was 19.6% in the no-vitamin
E subgroup, but just 6.7% in the vitamin E group. This indicates
that 12.9% of participants had no pneumonia by the age of 74
years because of vitamin E administration (69). Evidently, the
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effects of vitamin E for elderly men should be further examined
although negative findings even to the extent of harm have
been reported in some contexts.
CONCLUSIONS
This analysis of the ATBC Study found no support for the
“estimated average requirement” level of 12 mg/day. The strong
evidence of heterogeneity in the effects of vitamin E on mortality
in the ATBC Study supports the concept of “individuality in
nutrition” so that optimal doses for different population groups
can be quite different, depending on age and various life style
factors. In several subgroups of the ATBC Study and in several
other trials, vitamin E has caused harm at intakes much lower
than the stated tolerable upper intake level of 1 g/day. Thus, even
though doses in excess of 12 mg/day might be beneficial for some
groups of older males, they may also be harmful for some other
population groups. Further research is warranted on the effects
of vitamins E and C on males over 65 years.
DATA AVAILABILITY STATEMENT
Datasets generated for this study will not be made publicly
available. The dataset was given to the author on the
condition that he does not distribute it further. Requests to
access the dataset should be directed to Demetrius Albanes
albanesd@mail.nih.gov.
ETHICS STATEMENT
This is a secondary analysis of a previously published trial.
The participants provided their written informed consent to
participate in this study (18, 19).
AUTHOR CONTRIBUTIONS
HH planned the study, carried out the analyses, and wrote
the manuscript.
ACKNOWLEDGMENTS
The author thanks the ATBC study (The National Institute for
Health and Welfare, Finland, and the National Cancer Institute,
Rockville, MD, USA) for access to the data. The author had full
access to all of the data in this study and takes responsibility
for the accuracy of the data analysis. Parts of the discussion
section have previously been published in the thesis (37)
by the author.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fnut.2020.
00036/full#supplementary-material
REFERENCES
1. Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E,
Selenium and Carotenoids. National Academies Press,WashingtonDC (2000).
2. Horwitt MK, Century B, Zeman AA. Erythrocyte survival time and
reticulocyte levels after tocopherol depletion in man. Am J Clin Nutr. (1963)
12:99–106. doi: 10.1093/ajcn/12.2.99
3. Horwitt MK. Vitamin E and lipid metabolism in man. Am J Clin Nutr. (1960)
8:451–61. doi: 10.1093/ajcn/8.4.451
4. Fleming TR, DeMets DL. Surrogate end points in clinical trials:
are we being misled? Ann Intern Med. (1996) 125:605–13.
doi: 10.7326/0003-4819-125-7-199610010-00011
5. De Gruttola V, Fleming T, Lin DY, Coombs R. Validating surrogate
markers - are we being naive? J Infect Dis. (1997) 175:237–46.
doi: 10.1093/infdis/175.2.237
6. Temple, R. Are surrogate markers adequate to assess cardiovascular disease
drugs? JAMA. (1999) 282:790–5. doi: 10.1001/jama.282.8.790
7. Grimes DA, Schulz KF. Surrogate end points in clinical research:
hazardous to your health. Obstet Gynecol. (2005) 105:1114–8.
doi: 10.1097/01.AOG.0000157445.67309.19
8. Rothwell PM. External validity of randomised controlled trials: to
whom do the results of this trial apply? Lancet. (2005) 365:82–93.
doi: 10.1016/S0140-6736(04)17670-8
9. Institute of Medicine. Evaluation of Biomarkers and Surrogate Endpoints in
Chronic Disease. Washington, DC: National Academies Press (2010).
10. Stadtman ER. Protein oxidation and aging. Science. (1992) 257:1220–4.
doi: 10.1126/science.1355616
11. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the
degenerative diseases of aging. Proc Natl Acad Sci USA. (1993) 90:7915–22.
doi: 10.1073/pnas.90.17.7915
12. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging.
Science. (1996) 273:59–63. doi: 10.1126/science.273.5271.59
13. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing.
Nature. (2000) 408:239–47. doi: 10.1038/35041687
14. Ames BN. Low micronutrient intake may accelerate the degenerative diseases
of aging through allocation of scarce micronutrients by triage. Proc Natl Acad
Sci USA. (2006) 103:17589–94. doi: 10.1073/pnas.0608757103
15. Sohal RS, Orr WC. The redox stress hypothesis of aging. Free Radic Biol Med.
(2012) 52:539–55. doi: 10.1016/j.freeradbiomed.2011.10.445
16. Ames BN. Prolonging healthy aging: longevity vitamins and proteins. Proc
Natl Acad Sci USA. (2018) 115:10836–44. doi: 10.1073/pnas.1809045115
17. Meydani SN, Lewis ED, Wu D. Should vitamin E recommendations
for older adults be increased? Adv Nutr. (2018) 9:533–43.
doi: 10.1093/advances/nmy035
18. The ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-
carotene lung cancer prevention study: design, methods, participant
characteristics, and compliance. Ann Epidemiol. (1994) 4:1–10.
doi: 10.1016/1047-2797(94)90036-1
19. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The
effect of vitamin E and beta carotene on the incidence of lung cancer
and other cancers in male smokers. N Engl J Med. (1994) 330:1029–35.
doi: 10.1056/NEJM199404143301501
20. Hemilä H, Kaprio J. Modification of the effect of vitamin E supplementation
on the mortality of male smokers by age and dietary vitamin C. Am J
Epidemiol. (2009) 169:946–53. doi: 10.1093/aje/kwn413
21. Packer JE, Slater TF, Willson RL. Direct observation of a free radical
interaction between vitamin E and vitamin C. Nature. (1979) 278:737–8.
doi: 10.1038/278737a0
22. Sharma MK, Buettner GR. Interaction of vitamin C and vitamin E during free
radical stress in plasma: an ESR study. Free Rad Biol Med. (1993) 15:649–53.
doi: 10.1016/0891-5849(93)90146-L
23. Wijesundara MBJ, Berger S. The redox pair vitamin E and vitamin
c, a 13-C-NMR study. Liebigs Ann Chem. (1994) 12:1239–41.
doi: 10.1002/jlac.199419941216
Frontiers in Nutrition | www.frontiersin.org 9 March 2020 | Volume 7 | Article 36
Hemilä Requirement for Vitamin E
24. Huang J, May JM. Ascorbic acid spares alpha-tocopherol and prevents lipid
peroxidation in cultured h4IIE liver cells.Mol Cell Biochem. (2003) 247:171–6.
doi: 10.1023/a:1024167731074
25. Bendich A, D’Apolito P, Gabriel E, Machlin LJ. Interaction of dietary vitamin
C and vitamin E on guinea pig immune responses to mitogens. J Nutr. (1984)
114:1588–93. doi: 10.1093/jn/114.9.1588
26. Tanaka K, Hashimoto T, Tokumaru S, Iguchi H, Kojo S. Interactions between
vitamin C and vitamin E are observed in tissues of inherently scorbutic rats. J
Nutr. (1997) 127:2060–4. doi: 10.1093/jn/127.10.2060
27. Liu JF, Lee YW. Vitamin C supplementation restores the impaired vitamin
E status of guinea pigs fed oxidized frying oil. J Nutr. (1998) 128:116–22.
doi: 10.1093/jn/128.1.116
28. Hill KE,Montine TJ,Motley AK, Li X,May JM, Burk RF. Combined deficiency
of vitamins E and C causes paralysis and death in guinea pigs. Am J Clin Nutr.
(2003) 77:1484–8. doi: 10.1093/ajcn/77.6.1484
29. Hamilton IM, Gilmore WS, Benzie IF, Mulholland CW, Strain JJ. Interactions
between vitamins C and E in human subjects. Br J Nutr. (2000) 84:261–7.
doi: 10.1017/s0007114500001537
30. Bruno RS, Leonard SW, Atkinson J, Montine TJ, Ramakrishnan R, Bray
TM, et al. Faster plasma vitamin E disappearance in smokers is normalized
by vitamin C supplementation. Free Radic Biol Med. (2006) 40:689–97.
doi: 10.1016/j.freeradbiomed.2005.10.051
31. Pietinen P, Hartman AM, Haapa E, Räsänen L, Haapakoski J, Palmgren
J, et al. Reproducibility and validity of dietary assessment instruments.
I A self-administered food use questionnaire with a portion size picture
booklet. Am J Epidemiol. (1988) 128:655–66. doi: 10.1093/oxfordjournals.aje.a
115013
32. Heinonen M, Piironen V. The tocopherol, tocotrienol, and vitamin E content
of the average finnish diet. Int J Vitam Nutr Res. (1991) 61:27–32.
33. Hemilä H, Virtamo J, Albanes D, Kaprio J. Vitamin E and beta-carotene
supplementation and hospital-treated pneumonia incidence in male smokers.
Chest. (2004) 125:557–65. doi: 10.1378/chest.125.2.557
34. Hemilä H. Nutritional need versus optimal intake. Med Hypotheses. (1984)
14:135–9. doi: 10.1016/0306-9877(84)90051-3
35. Hemilä H. A critique of nutritional recommendations. J Orthomolecular
Psychiatry. (1985) 14:88-91. Available online at: http://orthomolecular.org/
library/jom/1985/pdf/1985-v14n02-p088.pdf
36. Hemilä H. A re-evaluation of nutritional goals - not just deficiency
counts. Med Hypotheses. (1986) 20:17–27. doi: 10.1016/0306-9877(86)
90082-4
37. Hemilä H. Do Vitamins C and E Affect Respiratory Infections? Ph.D. Thesis
University of Helsinki, Helsinki, Finland. (2006). p. 36–8,61–6. Available
online at: https://helda.helsinki.fi/handle/10138/20335
38. National Research Council. Recommended Dietary Allowances, 10th ed.
Washington, DC: National Academies Press (1989).
39. Food and Nutrition Board. How should the recommended
dietary allowances be revised? Nutr Revs. (1994) 52:216–9.
doi: 10.1111/j.1753-4887.1994.tb01425.x
40. Hemilä H. Is there a biochemical basis for ‘nutrient need’? Trends Food Sci
Technol. (1991) 2:73. doi: 10.1016/0924-2244(91)90626-T
41. Levine M. New concepts in the biology and biochemistry of ascorbic
acid. N Engl J Med. (1986) 314:892–902. doi: 10.1056/NEJM198604033
141407
42. Levine M, Hartzell W. Ascorbic acid: the concept of
optimum requirements. Ann NY Acad Sci. (1987) 498:424–44.
doi: 10.1111/j.1749-6632.1987.tb23779.x
43. Levine M, Dhariwal KR, Welch RW, Wang Y, Park JB. Determination
of optimal vitamin C requirements in humans. Am J Clin Nutr. (1995)
62:1347S−56S. doi: 10.1093/ajcn/62.6.1347S
44. Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function
approach yields pharmacology and therapeutic discoveries. Adv Nutr. (2011)
2:78–88. doi: 10.3945/an.110.000109
45. King CG. Vitamin C, ascorbic acid. Physiol Rev. (1936) 16:238–62.
doi: 10.1152/physrev.1936.16.2.238
46. Sigal A, King CG. The influence of vitamin C deficiency upon the resistance
of guinea pigs to diphtheria toxin. J Pharmacol Exp Ther. (1937) 61:1–9.
Available online at: https://jpet.aspetjournals.org/content/61/1/1
47. Pauling L. Orthomolecular psychiatry: varying the concentrations of
substances normally present in the human body may control mental disease.
Science. (1968) 160:265–71. doi: 10.1126/science.160.3825.265
48. Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates
variant enzymes with decreased coenzyme binding affinity (increased Km):
relevance to genetic disease and polymorphisms. Am J Clin Nutr. (2002)
75:616–58. doi: 10.1093/ajcn/75.4.616
49. Ames BN. Optimal micronutrients delay mitochondrial decay
and age-associated diseases. Mech Ageing Dev. (2010) 131:473–9.
doi: 10.1016/j.mad.2010.04.005
50. Ames BN. A role for supplements in optimizing health: themetabolic tune-up.
Arch Biochem Biophys. (2004) 423:227–34. doi: 10.1016/j.abb.2003.11.002
51. Williams RJ. Individuality in nutrition. In: Biochemical Individuality. Wiley
1956, reprinted by University of Texas Press, Austin, TX. (1979). p. 135–65.
52. Williams RJ, Pelton RB. Individuality in nutrition: effects of vitamin a-
deficient and other deficient diets on experimental animals. Proc Natl Acad
Sci USA. (1966) 55:126–34. doi: 10.1073/pnas.55.1.126
53. Williams RJ, Deason G. Individuality in vitamin C needs. Proc Natl Acad Sci
USA. (1967) 57:1638–41. doi: 10.1073/pnas.57.6.1638
54. Eckhardt RB. Genetic research and nutritional individuality. J Nutr. (2001)
131:336S−9S. doi: 10.1093/jn/131.2.336S
55. Kuhn TS. The Structure of Scientific Revolutions, 2nd ed. Chicago, IL:
University of Chicago Press. (1970).
56. Pauling L. The significance of the evidence about ascorbic acid and
the common cold. Proc Natl Acad Sci USA. (1971) 68:2678–81.
doi: 10.1073/pnas.68.11.2678
57. Hemilä H. Vitamin C and the common cold. Br J Nutr. (1992) 67:3–16.
doi: 10.1079/bjn19920004
58. Hemilä H, Chalker E. Vitamin C for preventing and treating the
common cold. Cochrane Database Syst Rev. (2013) 2013:CD000980.
doi: 10.1002/14651858.CD000980.pub4
59. Chalmers TC. Effects of ascorbic acid on the common cold: an evaluation of
the evidence. Am JMed. (1975) 58:532–6. doi: 10.1016/0002-9343(75)90127-8
60. Hemilä H, Herman ZS. Vitamin C and the common cold: a retrospective
analysis of chalmers’ review. J Am Coll Nutr. (1995) 14:116–23.
doi: 10.1080/07315724.1995.10718483
61. Hemilä H. Vitamin C supplementation and common cold symptoms:
problems with inaccurate reviews. Nutrition. (1996) 12:804–9.
doi: 10.1016/S0899-9007(96)00223-7
62. Kahneman D. Thinking, Fast and Slow. New York, NY: Farrar, Straus and
Giroux (2011).
63. Kunkel HO. Interests and values in the recommended dietary allowances
and nutritional guidelines for americans. J Nutr. (1996) 126:2390S−7S.
doi: 10.1093/jn/126.suppl_9.2390S
64. Beaton GH. When is an individual an individual versus a member of a group?
An issue in the application of the dietary reference intakes. Nutr Rev. (2006)
64:211–25. doi: 10.1111/j.1753-4887.2006.tb00204.x
65. Beaton GH. Reply to murphy, barr, and yates. Nutr Rev. (2006) 64:315–8.
doi: 10.1111/j.1753-4887.2006.tb00215.x
66. Hemilä H, Kaprio J. Vitamin E supplementation and pneumonia risk in males
who initiated smoking at an early age: effect modification by body weight and
dietary vitamin c. Nutr J. (2008) 7:33. doi: 10.1186/1475-2891-7-33
67. Hemilä H, Kaprio J. Subgroup analysis of large trials can guide further
research: a case study of vitamin E and pneumonia. Clin Epidemiol. (2011)
3:51–9. doi: 10.2147/CLEP.S16114
68. Hemilä H. Vitamin E and the risk of pneumonia: using the I2-statistic to
quantify heterogeneity within a controlled trial. Br J Nutr. (2016) 116:1530–6.
doi: 10.1017/S0007114516003408
69. Hemilä H. Vitamin E administration may decrease the incidence of
pneumonia in elderly males. Clin Interv Aging. (2016) 11:1379–85.
doi: 10.2147/CIA.S114515
70. Hemilä H, Virtamo J, Albanes D, Kaprio J. The effect of vitamin E on common
cold incidence is modified by age, smoking and residential neighborhood. J
Am Coll Nutr. (2006) 25:332–9. doi: 10.1080/07315724.2006.10719543
71. Hemilä H. The effect of β-carotene on common cold incidence is modified
by age and smoking: evidence against a uniform effect in a nutrient-disease
relationship. Nutrition Diet Suppl. (2010) 2:117–24. doi: 10.2147/NDS.S13299
Frontiers in Nutrition | www.frontiersin.org 10 March 2020 | Volume 7 | Article 36
Hemilä Requirement for Vitamin E
72. Hemilä H. Effect of β-carotene supplementation on the risk of pneumonia is
heterogeneous in males: effect modification by cigarette smoking. J Nutr Sci
Vitaminol. (2018) 64:374–8. doi: 10.3177/jnsv.64.374
73. Hemilä H, Kaprio J. Vitamin E may affect the life expectancy of men,
depending on dietary vitamin C intake and smoking. Age Ageing. (2011)
40:215–20. doi: 10.1093/ageing/afq178
74. Leppälä JM, Virtamo J, Fogelholm R, Huttunen JK, Albanes D, Taylor PR,
et al. Controlled trial of α-tocopherol and β-carotene supplements on stroke
incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol.
(2000) 20:230–5. doi: 10.1161/01.ATV.20.1.230
75. Leppälä JM, Virtamo J, Fogelholm R, Huttunen J.K, Albanes D, Taylor
PR, et al. Vitamin E and beta-carotene supplementation in high risk for
stroke: a subgroup analysis of the alpha-tocopherol, beta-carotene cancer
prevention study. Arch Neurol. (2000) 57:1503–9. doi: 10.1001/archneur.57.
10.1503
76. Hemilä H, Kaprio J. Vitamin E supplementation may transiently increase
tuberculosis risk in males who smoke heavily and have high dietary
vitamin C intake. Br J Nutr. (2008) 100:896–902. doi: 10.1017/S0007114508
923709
77. Hemilä H, Kaprio J. Vitamin E supplementation may transiently increase
tuberculosis risk in males who smoke heavily and have high dietary
vitamin C intake: reply by hemilä and kaprio. Br J Nutr. (2009) 101:146–7.
doi: 10.1017/S0007114508994423
78. Graat JM, Schouten EG, Kok FJ. Effect of daily vitamin E and multivitamin-
mineral supplementation on acute respiratory tract infections in elderly
persons. JAMA. (2002) 288:715–21. doi: 10.1001/jama.288.6.715
79. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, et al.
Effects of long-term vitamin E supplementation on cardiovascular events
and cancer: a randomized controlled trial. JAMA. (2005) 293:1338–47.
doi: 10.1001/jama.293.11.1338
80. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen
J, et al. Vitamins E and C in the prevention of cardiovascular
disease in men: the physicians’ health study II randomized
controlled trial. JAMA. (2008) 300:2123–33. doi: 10.1001/jama.20
08.600
81. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman
PJ, et al. Vitamin E and the risk of prostate cancer: the selenium and
vitamin E Cancer prevention trial (SELECT). JAMA. (2011) 306:1549–56.
doi: 10.1001/jama.2011.1437
82. Horwitt MK. Critique of the requirement for vitamin e.Am J Clin Nutr. (2001)
73:1003–5. doi: 10.1093/ajcn/73.6.1003
83. Liede KE, Haukka JK, Saxén LM, Heinonen OP. Increased tendency
towards gingival bleeding caused by joint effect of alpha-tocopherol
supplementation and acetylsalicylic acid. Ann Med. (1998) 30:542–6.
doi: 10.3109/07853899709002602
Conflict of Interest: The author declares that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Hemilä. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Nutrition | www.frontiersin.org 11 March 2020 | Volume 7 | Article 36
